Citations

Showing 10 of 108094 citations.

Patient reminder and recall interventions to improve immunization rates
Vann, Julie C. Jacobson , Coyne‐Beasley, Tamera , Asafu‐Adjei, Josephine , Szilagyi, Peter G. , Jacobson, Robert M.

Mayo Clinic

Cochrane Database of Systematic Reviews | January 18, 2018 | Volume: 2018 | Issue: 1 | Pages: No page available

10.1002/14651858.cd003941.pub3 | PMID 29342498 Get It

Function, Shoulder Motion, Pain, and Lymphedema in Breast Cancer With and Without Axillary Web Syndrome: An 18-Month Follow-Up
Koehler, Linda , Hunter, David W. , Haddad, Tufia C. , Blaes, Anne

Mayo Clinic

Physical Therapy | January 18, 2018 | Volume: 98 | Issue: 6 | Pages: 518-527

10.1093/ptj/pzy010 | PMID 29361075 Get It

Abstract Background Axillary web syndrome (AWS) can develop following breast cancer surgery and presents as a tight band of tissue in the axilla with shoulder abduction. Objective The objectives were to determine the prevalence and natural history of AWS and the association between AWS and function, range of motion, pain, lymphedema, and body mass index (BMI). Design This study was a longitudinal prospective cohort study utilizing a repeated measures design. Methods Axillary web syndrome, function, shoulder range of motion, pain, and lymphedema (using circumference, bioimpedance spectroscopy, tissue dielectric constant) were assessed in women at 2, 4, and 12 weeks and 18 months following breast cancer surgery. Prevalence of AWS and the association with the measured outcomes were analyzed. Results Thirty-six women agreed to participate in the study. The cumulative prevalence of AWS was 50% (18/36) at 18 months following breast cancer surgery. AWS was identified as a risk factor for reduced function. Women with AWS had statistically reduced range of motion, lower BMI, and higher number of lymph nodes removed compared to the non-AWS group. Forty-one percent (13/32) of women had AWS at 18 months. AWS reoccurred in 6 women following resolution, and a new case developed beyond the early postoperative period. The overall prevalence of physical impairments ranged from 66% to 97% within the first 18 months following surgery regardless of AWS. Limitations Limitations include a small sample size and potential treatment effect. Conclusion AWS occurs in approximately 50% of women following breast cancer surgery. It can persist for 18 months and potentially longer, develop beyond the early postoperative time period, and reoccur after resolution. Clinicians need to be aware of the chronicity of AWS and its association with reduced range of motion and function.
Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update
Ismaila, Nofisat , Flynn, Patrick J. , Halabi, Susan , Ogaily, Mohammed S., Omel, Jim, Roodman, G. David, Yee, Gary C., Kyle, Robert A. , Halabi, Susan , Anderson, Kenneth C. , Jagannath, Sundar , Raje, Noopur

Mayo Clinic

Journal of Clinical Oncology | January 17, 2018 | Volume: 36 | Issue: 8 | Pages: 812-818

10.1200/jco.2017.76.6402 | PMID 29341831 Get It

Purpose To update guideline recommendations on the role of bone-modifying agents in multiple myeloma. Methods An update panel conducted a targeted systematic literature review by searching PubMed and the Cochrane Library for randomized controlled trials, systematic reviews, meta-analyses, clinical practice guidelines, and observational studies. Results Thirty-five relevant studies were identified, and updated evidence supports the current recommendations. Recommendations For patients with active symptomatic multiple myeloma that requires systemic therapy with or without evidence of lytic destruction of bone or compression fracture of the spine from osteopenia on plain radiograph(s) or other imaging studies, intravenous administration of pamidronate 90 mg over at least 2 hours or zoledronic acid 4 mg over at least 15 minutes every 3 to 4 weeks is recommended. Denosumab has shown to be noninferior to zoledronic acid for the prevention of skeletal-related events and provides an alternative. Fewer adverse events related to renal toxicity have been noted with denosumab compared with zoledronic acid and may be preferred in this setting. The update panel recommends that clinicians consider reducing the initial pamidronate dose in patients with preexisting renal impairment. Zoledronic acid has not been studied in patients with severe renal impairment and is not recommended in this setting. The update panel suggests that bone-modifying treatment continue for up to 2 years. Less frequent dosing has been evaluated and should be considered in patients with responsive or stable disease. Continuous use is at the discretion of the treating physician and the risk of ongoing skeletal morbidity. Retreatment should be initiated at the time of disease relapse. The update panel discusses measures regarding osteonecrosis of the jaw. Additional information is available at www.asco.org/hematologic-malignancies-guidelines and www.asco.org/guidelineswiki .
Deficient Glucagon Response to Hypoglycemia During a Mixed Meal in Total Pancreatectomy/Islet Autotransplantation Recipients
Bogachus, Lindsey D., Robertson, R. Paul , Bellin, Melena D. , Vella, Adrian

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | January 17, 2018 | Volume: 103 | Issue: 4 | Pages: 1522-1529

10.1210/jc.2017-02182 | PMID 29351616 Get It

Utility of Noncontrast Magnetic Resonance Imaging for Detection of Recurrent Vestibular Schwannoma
Williams, Jamie C., Eckel, Laurence J. , Carlson, Matthew L. , Lane, John I. , Carr, Carrie M. , Kotsenas, Amy L. , Hunt, Christopher H.

Mayo Clinic

Otology & Neurotology | January 17, 2018 | Volume: 39 | Issue: 3 | Pages: 372-377

10.1097/mao.0000000000001698 | PMID 29342038 Get It

Background: Gadolinium-enhanced T1-weighted magnetic resonance imaging (MRI) (T1WI) is the conventional imaging technique of choice to detect vestibular schwannoma (VS) recurrence or regrowth, despite suboptimal specificity secondary to enhancing postoperative changes. Furthermore, recent concerns regarding the accumulation of gadolinium in body tissues have led for a call to reduce the number of contrast-enhanced examinations. The objective of the current study is to evaluate the diagnostic accuracy of high-resolution noncontrast (three-dimensional [3D] T2) MRI relative to gadolinium-enhanced T1WI in the detection of VS recurrence after resection. Methods: Following Institutional Review Board approval, 13 consecutive postoperative patients with VS recurrence or regrowth were identified from a prospectively maintained clinical database in which recurrence was determined by progression on serial postoperative MRI examination. Three blinded neuroradiologists retrospectively evaluated a total of 41 postoperative MRI examinations from these patients using only gadolinium-enhanced T1WI and 3D T2 MRI for recurrence or regrowth. Interobserver agreement, differences in detection between the two sequences, and the sensitivity and specificity of 3D T2 MRI were assessed. Results: Fifteen of the 41 postoperative MRIs demonstrated progression, as determined by examiner consensus on the gadolinium-enhanced T1WI. Agreement, measured using Krippendorff's alpha, was 0.82 for the 3D T2 images and 0.83 for the contrast-enhanced T1WI. All the three examiners demonstrated no difference in the detection of progression between the two sequences (McNemar's test p values 0.69 for examiner 1, 0.63 for examiner 2, and 0.99 for examiner 3). The sensitivity of 3D T2 was 0.78 (CI 0.60–0.96), while the specificity was 0.94 (CI 0.86–1.00). Conclusion: Noncontrast high-resolution 3D T2 MRI seems sufficient to assess for recurrence or regrowth after VS resection. The results of this study have implications for reducing cost, time, and adverse events associated with gadolinium administration in this population requiring serial follow-up examinations. These promising, yet preliminary findings warrant confirmation with a larger prospective cohort of patients.
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
Kyle, Robert A. , Therneau, Terry M. , Kumar, Shaji , Larson, Dirk R. , Dispenzieri, Angela , Cerhan, James R. , Rajkumar, S. Vincent

Mayo Clinic

New England Journal of Medicine | January 17, 2018 | Volume: 378 | Issue: 3 | Pages: 241-249

10.1056/nejmoa1709974 | PMID 29342381 Get It

Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype
Jain, Apurva , Kelley, Robin Kate , Wáng, Ying , Baggerly, Keith, Al‐Shamsi, Humaid O. , Ahn, Daniel H. , DeLeon, Thomas, Bocobo, Andrea Grace, Bekaii‐Saab, Tanios , Shroff, Rachna T. , Javle, Milind , Abdel-Wahab, Reham, Meric-Bernstam, Funda, Baggerly, Keith A, Kaseb, Ahmed Omar, Al-Shamsi, Humaid O, Bekaii-Saab, Tanios S , Borad, Mitesh J. , Abdel‐Wahab, Reham , Meric‐Bernstam, Funda , Kaseb, Ahmed O , Al-Shamsi, Humaid O

Mayo Clinic

JCO Precision Oncology | January 17, 2018 | Volume: No volume available | Issue: 2 | Pages: 1-12

10.1200/po.17.00080 | PMID 35135097 Get It

Purpose FGFR genetic aberrations (GAs) occur in an estimated 10% to 16% of intrahepatic cholangiocarcinomas (CCAs). The natural history of CCA with FGFR GAs, the prognostic role of coexisting GAs, and the outcome with FGFR-targeted inhibitors are unknown. Patients and Methods Patients with CCA with FGFR GAs were identified using next-generation sequencing or fluorescence in situ hybridization from four tertiary cancer centers and compared with FGFR wild-type counterparts. Data reviewed included demographic, treatment, overall survival (OS), and GA data. Fisher’s exact test, Kaplan-Meier plots, and log-rank tests were used for statistical analysis. Results Three hundred seventy-seven patients with CCA were identified, and 95 had FGFR GAs. FGFR2 GA was most common (n = 74, with 63 fusions) and seen in intrahepatic CCA. In patients with CCA, FGFR GAs occurred more frequently in younger patients (≤ 40 years; 20%) compared with older patients (> 40 years; 6.7%; P < .001), presented at an earlier stage (TNM stage I/II v III/IV: 35.8% v 22%, respectively; P = .001), and were associated with a longer OS compared with patients without FGFR GAs (37 v 20 months, respectively; P < .001). This difference remained significant after excluding 36 patients treated with FGFR inhibitors. There was no OS difference ( P = .60) between CCA with FGFR2 fusions (n = 63) versus other FGFR GAs (n = 29). Patients with FGFR GAs had a better OS with FGFR-targeted therapy compared with standard treatment ( P = .01). BAP1 mutation was the most common coexisting mutation without prognostic impact, whereas TP53 ( P = .04) and CDKN2A/B ( P = .04) were correlated with a shorter OS. Conclusion CCA with FGFR GAs represents a unique subtype occurring in younger patients with an indolent disease course. FGFR-targeted therapy may have a positive impact on OS in this subgroup.
Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett’s esophagus
Moinova, Helen , LaFramboise, Thomas , Lutterbaugh, James, Chandar, Apoorva K., Dumot, John A. , Faulx, Ashley L., Brock, Wendy , Cabrera, Omar De la Cruz , Guda, Kishore , Barnholtz‐Sloan, Jill S. , Iyer, Prasad G. , Wang, Jean S. , Shaheen, Nicholas J. , Thota, Prashanti N., Willis, Joseph , Chak, Amitabh , Markowitz, Sanford D. , Moinova, Helen R , De la Cruz Cabrera, Omar , Willis, Joseph E , Chak, Amitabh , Markowitz, Sanford D , Barnholtz-Sloan, Jill S , Canto, Marcia Irene

Mayo Clinic

Science Translational Medicine | January 17, 2018 | Volume: 10 | Issue: 424 | Pages: No page available

10.1126/scitranslmed.aao5848 | PMID 29343623 Get It

Combining DNA methylation markers with a swallowable device for sampling the distal esophagus effectively detects Barrett’s neoplasias.
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
Calkins, Hugh , Hindricks, Gerhard , Cappato, Riccardo , Kim, Young‐Hoon , Aguinaga, Luis, Akar, Joseph G. , Badhwar, Vinay , Camm, A. John , Chen, Peng‐Sheng , Chen, Shih‐Ann , Chung, Mina K. , Nielsen, Jens Cosedis , Curtis, Anne B. , Davies, D. Wyn, Groot, Natasja M.S. de , Duytschaever, Mattias , Edgerton, James R. , Ellenbogen, Kenneth A. , Ernst, Sabine , Fenelon, Guilherme , Gerstenfeld, Edward P. , Haines, David E. , Haïssaguerre, Michel , Jackman, Warren M. , Jalife, José , Kalman, Jonathan M. , Kautzner, Josef , Kottkamp, Hans , Kuck, Karl Heinz, Kumagai, Koichiro , Lee, Richard, Lewalter, Thorsten , Lindsay, Bruce D., Mansour, Moussa , Michaud, Gregory F., Nakagawa, Hiroshi , Natale, Andrea , Okumura, Ken , Packer, Douglas L. , Reynolds, Matthew R. , Sanders, Prashanthan , Scanavacca, Maurício , Schilling, Richard J. , Tondo, Claudio , Tsao, Hsuan-Ming, Verma, Atul , Wilber, David J. , Reviewers:, Document, Paola, Ângelo Amato Vincenzo de , Kistler, Peter M. , Pisani, Cristiano , Raviele, Antonio , Satomi, Kazuhiro , Stiles, Martin K. , Willems, Stephan , Haı̈ssaguerre, Michel , Packer, Douglas, Verma, Atul , Natale, Andrea , Sanders, Prashanthan , Nielsen, Jens C , de Groot, Natasja M S , Saad, Eduardo , Brugada, Josép , Day, John , d'Avila, Andre , Biase, Luigi Di , Ellinor, Patrick T. , Haissaguerre, Michel , Helm, Robert H. , Hylek, Elaine M. , Macle, Laurent , Marchlinski, Francis E. , Michaud, Gregory F. , Nattel, Stanley , Pokushalov, Evgeny A. , Tsao, Hsuan-Ming, Yamane, Teiichi , Reviewers:, Document, Blomström‐Lundqvist, Carina , Lip, Gregory Y H , Peters, Nicholas Simon , Scanavacca, Maurício , Tondo, Claudio , Ernst, Sabine , Ellenbogen, Kenneth A

Mayo Clinic

EP Europace | January 17, 2018 | Volume: 20 | Issue: 1 | Pages: e1-e160

10.1093/europace/eux274 | PMID 29016840 Get It